Humacyte (HUMA) Peer Comparison

$0.44

$0.00 (0.09%)

As on 16-Oct-2026 13:36EDT

Market cap

$113 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

--

P/B Ratio

5

Div. Yield

0 %

Edit

	Humacyte (HUMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	113	17,083	15,084	14,832	12,532
Revenue ($ Mln)	2	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	-96.74	491.50	755.85	860.62	413.60
Net Margin (%)	-4,560.82	17.67	71.69	35.33	24.86
RoE (%)	-562.90	110.09	--	42.98	430.03
Price to Earnings	--	35.94	17.57	18.88	32.29
Price-To-Book	5.01	39.70	8.91	7.82	88.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Humacyte (HUMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	2.12	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	16.26	1,982.07	103.47	85.67	292.42
Gross Profit	-15.01	760.62	588.53	2,236.43	1,167.84
Operating Expenses	97.01	216.81	841.45	1,378.74	440.53
Operating Profit (EBIT)	-111.16	583.40	109.45	971.51	930.79
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-96.74	598.92	101.11	1,035.47	583.34
Provision for Tax	0.00	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	-96.74	491.50	755.85	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Humacyte (HUMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	31.26	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	91.88	187.89	384.48	288.55	2,089.43
Current Liabilities	14.95	1,435.43	464.70	361.93	344.44
Total Liabilities	116.37	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Humacyte (HUMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	45.30	1,006.90	895.24	1,243.41	1,644.38
Current Assets	92.79	1,050.29	1,389.84	1,250.82	933.02
Total Assets	116.37	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	66.18	144.11	449.89	165.93	2,146.65
Net Current Assets	77.84	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Humacyte (HUMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-105.04	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	-0.88	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	61.49	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Humacyte (HUMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	-256.63	57.43	-30.01	32.82	15.61
ROE (%)	-562.90	110.09	163.18	42.98	430.03
ROA (%)	-61.83	15.64	31.68	29.32	16.19
EBIT Margin (%)	-4,075.34	21.13	5.73	41.82	36.28
Net Margin (%)	-4,560.82	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Humacyte (HUMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	-73.64	24.67	114.85	9.23	41.15
EBIT Growth (%)	-79.44	18.70	136.39	29.37	-14.99
Net Profit Growth (%)	-64.91	17.50	378.76	42.89	-25.78
EPS Growth (%)	-14.07	26.84	353.27	50.42	-23.48
Book Value Growth (%)	412.08	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Humacyte (HUMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-3.72	36.06	-59.76	15.79	24.99
Price / Book Value	48.86	35.44	-80.42	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-7.48	27.88	-121.54	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Humacyte (HUMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	1.16	0.00	0.27	0.00	13.50
Short term debt to equity ratio	0.05	0.06	0.05	0.00	1.46
Current Ratio	6.21	0.73	2.99	3.46	2.71
Quick Ratio	5.74	0.73	2.32	3.38	2.31
Interest Coverage	-8.39	--	1.62	--	29.73

Operating Efficiency Ratios

	Humacyte (HUMA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	15.56	15.88	21.25	13.74	27.40
Asset Turnover	0.01	0.89	0.44	0.83	0.65
Receivable days	39.52	50.42	85.52	43.48	98.04
Inventory Days	145.58	--	1,056.70	96.17	254.12
Payable days	105.99	6.26	331.01	147.97	24.86
Cash Conversion Cycle	79.10	--	811.21	-8.32	327.29

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly